Past Events

Join us for a fireside chat featuring Jennifer Tegan, Managing Director of New York Ventures for Empire State Development. In conversation with a Cornell Entrepreneur in Residence, Jennifer will explore how New York State strengthens its entrepreneurial ecosystem by expanding access to venture capital and supporting high-growth companies. 

Whether you’re a founder, investor, or ecosystem builder, this conversation offers valuable insight into how public investment supports startup growth across the state. 

Register here. 

Are you a STEM researcher interested in making an impact with your technology innovation? The National Science Foundation’s I-Corps program can provide you with professional training, mentoring, and up to $50,000 in funding for customer discovery.  

Hosted by the Interior Northeast I-Corps Hub (IN I-Corps), the virtual NSF I-Corps Information Session is designed for busy graduate students, postdocs, and faculty interested in learning more about I-Corps regional and national programming. NSF I-Corps instructor Shannon Collins and program alum Paola Calderon will be in attendance to share their experience and answer questions.  

The NSF created I-Corps (Innovation Corps) to bridge the gap between fundamental research discoveries in science and engineering and the commercialization of technologies, products, and processes with the potential to benefit society.   

Register here.  

Please mark your calendars for this year’s BioInnovate Program Series celebrating life science innovators from Weill Cornell Medicine as well as startup representatives from Cornell University and Cornell Tech.

Join leading investors and industry representatives from organizations including Healthwrx, EpiVax, Fusion Fund, LabyRx, Scion Life Sciences, L.E.K. Consulting, Qiming Venture Partners, and Regeneron for a dynamic series of conversations and events.

With more than 21,000 drug programs in the global R&D pipeline, you might expect a surge in new biological targets. Instead, novel targets entering development have fallen from ~100 per year a decade ago to about 30 in 2024, while 25% of drug-target pairs focus on just 38 well-known targets.

As AI, new modalities, and cell therapies expand the frontier of drug discovery, what does it take to build the chain of evidence investors and industry partners need to back a novel target? Join our upcoming panel to find out.

Register here. 

Why does health IT still frustrate so many healthcare stakeholders? Why were early systems designed with limited clinician input? Can AI help fix the problems created by legacy systems?

You’re invited to join us for a conversation with Dr. S. Yin Ho, author of Rushing Headlong: Health IT’s Legacy and the Road to Responsible AI. 

In her new book, Dr. Ho examines how the early architecture of health information technology shaped the systems that clinicians and researchers struggle with today. As generative AI arrives, those same structural choices may determine whether AI ultimately better serves practitioners and patients or simply adds another layer of complexity.

Dr. Ho is a serial entrepreneur and visionary executive in health IT and clinical research with more than 25 years of experience founding, building, and leading healthcare technology companies and initiatives.  Most recently, she served as Interim CEO of Veradigm, where she led the strategic acquisition of generative AI company ScienceIO. Under her leadership, Veradigm became the first electronic health record company to develop proprietary small language models in-house—an effort aimed at improving the quality of clinical data used for both care and research.

Join us for a candid discussion about the past, present, and future of health IT.  Register here.